Neurolief announced today that it received FDA breakthrough device designation for its Relivion DP system for treating major depression.
Relivion is a wearable, non-invasive, multi-channel brain neuromodulation device designed as an adjunctive treatment to pharmaceutical management of major depressive disorder (MDD) in adults who haven’t experienced satisfactory improvement from antidepressant medications, according to a news release. [Read more…] about Neuromodulation device Relivion gets FDA clearance to help patients with major depression who don’t benefit from antidepressant medications
Around 350 million people worldwide have depression. Antidepressant medications are often prescribed to treat the condition, alongside talking therapies and lifestyle changes such as regular exercise.
But a substantial proportion of people either don’t respond to antidepressants, or experience such significant side effects that they’d prefer not to take them.